President Droupadi Murmu is set to visit the Indian Institute of Technology (IIT) Bombay today, April 4, to dedicate India's indigenous CAR-T Cell Therapy, to the nation. Termed as a "living drug", CAR-T Cell Therapy has been developed as a collaborative effort between IIT Bombay and Tata Memorial Centre (TMC), for advanced blood cancer treatment.

The CAR-T Cell Therapy is expected to save many lives at a much lower cost, compared to the exorbitant prices outside of India. From ₹5 crore expense in the US, Indian patients can now avail this therapy at a significantly reduced cost of ₹40 lakh, rendering it accessible to many.

Designed and developed at IIT Bombay, the therapy has undergone integrative process development and manufacturing, at ImmunoACT. Clinical investigations and translational studies were conducted by teams at Tata Memorial Hospital (TMH). This technology was first developed in the USA, back in 2010.